Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 337 in Asian subjects with advanced solid tumors
NCT02096666Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AMG-337 in solid tumor, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 1 more, sponsored by Amgen. Primary endpoints: Adverse events and clinical laboratory abnormalities at 17 months and Overall Response Rate at 17 months. Started Apr 2014; status: completed.
02
Drugs
AMG-337
03
Conditions
solid tumorgastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT02096666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096666.